Allos Therapeutics (ALTH) Announces Presentation of Phase 1/2 Trials of PDX in Patients with Relapsed or Refractory non-Hodgkin's Lymphoma and Hodgkin's Disease
Tweet Send to a Friend
Allos Therapeutics, Inc. (Nasdaq: ALTH) announced the presentation of interim results from its on-going Phase 1/2 trial of PDX (pralatrexate) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
